Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.75 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.60 |
| ▸ | CASP2 | P42575 | 2/20 | 0.87 |
| ▸ | UBE2N | P61088 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | CA12 | O43570 | 5/20 | 0.75 |
| ▸ | CA6 | P23280 | 5/20 | 0.75 |
| ▸ | CA7 | P43166 | 5/20 | 0.75 |
| ▸ | CA9 | Q16790 | 5/20 | 0.75 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.75 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.75 |
| ▸ | CA4 | P22748 | 4/20 | 0.75 |
| ▸ | CA5A | P35218 | 4/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.75 |
| ▸ | F13A1 | P00488 | 2/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15226686 | 0.97 | CASP2 (0.93) | CASP2UBE2NMAPTPMP22KDM4E | |
| SCHEMBL14514463 | 0.97 | CASP2 (0.93) | CASP2UBE2NMAPTPMP22KDM4E | |
| Hydrochloric Acid SCHEMBL8977288 | 0.97 | CASP2 (0.93) | CASP2UBE2NMAPTPMP22KDM4E | |
| SCHEMBL1888585 | 0.97 | CASP2 (0.93) | CASP2UBE2NMAPTPMP22KDM4E | |
| Norspermidine SCHEMBL10620364 | 0.97 | CASP2 (0.93) | CASP2UBE2NMAPTPMP22KDM4E | |
| Trientine SCHEMBL8736113 | 0.97 | CASP2 (0.93) | CASP2UBE2NMAPTPMP22KDM4E | |
| SCHEMBL19257489 | 0.93 | CASP2 (0.87) | CASP2UBE2NMAPTPMP22KDM4E | |
| SCHEMBL11365907 | 0.93 | CASP2 (0.87) | CASP2UBE2NMAPTPMP22KDM4E | |
| Spermine SCHEMBL4275609 | 0.93 | CA12 (0.87) | CASP2UBE2NMAPTPMP22KDM4E | |
| SCHEMBL6251209 | 0.93 | CA12 (0.86) | CASP2UBE2NMAPTPMP22KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951890-B2 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PROTEMIX CORPORATION LIMITED (NZ) | 2005-10-04 | — | — | US | claimed |
| US-20030203973-A1 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PHILERA NEW ZEALAND LIMITED (NZ) | 2003-10-30 | — | — | US | claimed |
| US-20220331275-A1 | COMBINATION TREATMENTS FOR CENTRAL NERVOUS SYSTEM DISORDERS | PHILERA NEW ZEALAND LTD. (NZ) | 2022-10-20 | — | — | US | disclosed |
| CN-114867474-A | Combination therapy for central nervous system disorders | 菲勒拉新西兰有限责任公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-3982943-A1 | COMBINATION TREATMENTS FOR CENTRAL NERVOUS SYSTEM DISORDERS | Philera New Zealand Ltd. (NZ) | 2022-04-20 | — | — | EP | disclosed |
| WO-2021152584-A1 | METHODS OF ANALYZING CELL MEMBRANES | Ariel Scientific Innovations Ltd. (IL) | 2021-08-05 | — | — | WO | disclosed |
| US-8987244-B2 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PHILERA NEW ZEALAND LIMITED (NZ) | 2015-03-24 | — | — | US | disclosed |
| US-20140113969-A1 | Preventing And/Or Treating Cardiovascular Disease And/Or Associated Heart Failure | PHILERA NEW ZEALAND LIMITED (NZ) | 2014-04-24 | — | — | US | disclosed |
| US-8563538-B2 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PHILERA NEW ZEALAND LIMITED (NZ) | 2013-10-22 | — | — | US | disclosed |
| EP-2500018-A1 | Preventing and/or Treating Cardiovascular Disease and/or Associated Heart Failure | PhilERA New Zealand Limited (NZ) | 2012-09-19 | — | — | EP | disclosed |
| EP-1487431-B1 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | PHILERA NEW ZEALAND LTD (NZ) | 2012-05-02 | — | — | EP | disclosed |
| WO-2004017957-A1 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2004-03-04 | — | — | WO | disclosed |
| US-20030232799-A1 | Copper chelators for treating ocular Inflammation | LI, NING, DR. (CN) | 2003-12-18 | — | — | US | disclosed |
| EP-1370254-A2 | COPPER CHELATORS FOR TREATING OCULAR INFLAMMATION | The University of British Columbia (CA) | 2003-12-17 | — | — | EP | disclosed |
| US-20030203973-A1 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PHILERA NEW ZEALAND LIMITED (NZ) | 2003-10-30 | — | — | US | disclosed |
| WO-2003077901-A1 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003075910-A1 | PREVENTING AND/OR TREATING VASCULAR DISEASE, CARDIOMYOPATHY AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2003-09-18 | — | — | WO | disclosed |
| US-20030055113-A1 | Copper chelators for treating ocular inflammation | UNIVERSITY OF BRITISH COLUMBIA, THE (CA) | 2003-03-20 | — | — | US | disclosed |
| US-20030035917-A1 | Image making medium | HYMAN SYDNEY (US) | 2003-02-20 | — | — | US | disclosed |
| WO-2002043722-A2 | COPPER CHELATORS FOR TREATING OCULAR INFLAMMATION | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203973-A1 | Preventing and/or treating cardiovascular disease and/or associated heart failure | TNNI3, FABP3, TNNT2 | CA2 420/4885ESR1 2669/4885CASP2 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.